Main navigation

Products we regulate
Product safety
How we regulate
Guidance and resources

Mayne Pharma International Pty Ltd

Regulatory activities for this sponsor.

- LinkedIn
- (Twitter)
- Facebook
- Email

Loading...

Type

ARTG (59)
Cancellation by sponsor (34)
Australian Public Assessment Report (AusPAR) (5)
Prescription medicine registration (5)
Prescription medicine decision summary (1)

Date

2024 (2)
2023 (14)
2022 (11)
2021 (5)
2020 (9)
2019 (4)
2018 (13)
2017 (7)
2015 (2)
2014 (3)
2013 (3)
2012 (4)
2010 (1)
2009 (1)
2007 (1)
2004 (2)
2002 (1)
1999 (1)
1998 (1)
1996 (6)
1994 (3)
1991 (10)

Results for "[search-keyword]"

Search

Sponsor content

104 result(s) found, displaying 51 to 60

AusPAR: Morphine sulfate pentahydrate

21 March 2019

Australian Public Assessment Report (AusPAR)

Australian Public Assessment Report for Morphine sulfate pentahydrate
KAPANOL (Mayne Pharma International Pty Ltd)

6 February 2019

Prescription medicine registration

Active ingredients: morphine sulfate pentahydrate.
AusPAR: Fosfomycin trometamol

7 September 2018

Australian Public Assessment Report (AusPAR)

Australian Public Assessment Report for Fosfomycin trometamol
DORYX 100 doxycycline 100mg (as hydrochloride) capsule blister pack Cancelled under Section 30(1)(c) of the Act

13 June 2018

Cancellation by sponsor

Requested by Mayne Pharma International Pty Ltd
DORYX 50 doxycycline 50mg (as hydrochloride) capsule blister pack Cancelled under Section 30(1)(c) of the Act

13 June 2018

Cancellation by sponsor

Requested by Mayne Pharma International Pty Ltd
MAYNE PHARMA DOXYCYCLINE doxycycline (as hydrochloride) 100mg capsule blister pack Cancelled under Section 30(1)(c) of the Act

13 June 2018

Cancellation by sponsor

Requested by Mayne Pharma International Pty Ltd
MAYNE PHARMA DOXYCYCLINE doxycycline (as hydrochloride) 50mg capsule blister pack Cancelled under Section 30(1)(c) of the Act

13 June 2018

Cancellation by sponsor

Requested by Mayne Pharma International Pty Ltd
ERYC erythromycin 250mg capsule blister pack Cancelled under Section 30(1)(c) of the Act

13 June 2018

Cancellation by sponsor

Requested by Mayne Pharma International Pty Ltd
MAYNE PHARMA ERYTHROMYCIN erthromycin 250mg capsule blister pack Cancelled under Section 30(1)(c) of the Act

13 June 2018

Cancellation by sponsor

Requested by Mayne Pharma International Pty Ltd
EPOPROSTENOL MYX epoprostenol (as sodium) 500 microgram powder for injection vial with diluent vial Cancelled under Section 30(1)(c) of the Act

30 April 2018

Cancellation by sponsor

Requested by Mayne Pharma International Pty Ltd

Pages

First page
Previous page
…
Page 2
Page 3
Page 4
Page 5
Current page 6
Page 7
Page 8
Page 9
Page 10
…
Next page
Last page

Is there anything wrong with this page?

Help us improve the Therapeutic Goods Administration site

What were you doing? (mandatory)

What went wrong? (mandatory)

Leave this field blank

Using our website

Accessibility
Privacy
Disclaimer
Copyright
Freedom of information

Quick links

Search our databases
Report a problem or side effect
TGA Business Services
Special Access Scheme
Authorised Prescriber
Office of Drug Control
State and territory contacts

Connect with us

Subscribe to updates
Contact us
Facebook
(Twitter)
Youtube
Instagram
LinkedIn

Help us improve

We are always looking for ways to improve our website.

Provide feedback

The Department of Health and Aged Care acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.